TY - JOUR AU - Tangcharoensathien, V. AU - Patcharanarumol, W. AU - Ir, P. AU - Aljunid, S. AU - Mukti, A. AU - Akkhavong, K. AU - Banzon, E. AU - Huong, D. AU - Thabrany, H. AU - Mills, A. PY - 2011 DA - 2011// TI - Health-financing reforms in Southeast Asia: challenges in achieving universal coverage JO - Lancet VL - 377 UR - https://doi.org/10.1016/S0140-6736(10)61890-9 DO - 10.1016/S0140-6736(10)61890-9 ID - Tangcharoensathien2011 ER - TY - STD TI - World Health Organization: What is Universal Health Coverage?http://www.who.int/features/qa/universal_health_coverage/en/. Accessed February 23, 2015. UR - http://www.who.int/features/qa/universal_health_coverage/en/ ID - ref2 ER - TY - BOOK AU - Freemantle, N. AU - Hill, S. PY - 2004 DA - 2004// TI - Evaluating Pharmaceuticals for Health Policy and Reimbursement PB - Blackwell CY - Oxford, UK UR - https://doi.org/10.1002/9780470994719 DO - 10.1002/9780470994719 ID - Freemantle2004 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. AU - Day, R. AU - March, L. AU - Sansom, L. AU - Bertouch, J. PY - 2004 DA - 2004// TI - Access to high cost drugs in Australia JO - BMJ VL - 329 UR - https://doi.org/10.1136/bmj.329.7463.415 DO - 10.1136/bmj.329.7463.415 ID - Lu2004 ER - TY - JOUR AU - Walker, S. AU - Sculpher, M. AU - Claxton, K. AU - Palmer, S. PY - 2012 DA - 2012// TI - Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions JO - Value Health VL - 15 UR - https://doi.org/10.1016/j.jval.2011.12.013 DO - 10.1016/j.jval.2011.12.013 ID - Walker2012 ER - TY - JOUR AU - Sansom, L. PY - 2004 DA - 2004// TI - The subsidy of pharmaceuticals in Australia: processes and challenges JO - Aust Health Rev VL - 28 UR - https://doi.org/10.1071/AH040194 DO - 10.1071/AH040194 ID - Sansom2004 ER - TY - JOUR AU - Jirawattanapisal, T. AU - Kingkaew, P. AU - Lee, T. J. AU - Yang, M. C. PY - 2009 DA - 2009// TI - Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan JO - Value Health VL - 12 UR - https://doi.org/10.1111/j.1524-4733.2009.00620.x DO - 10.1111/j.1524-4733.2009.00620.x ID - Jirawattanapisal2009 ER - TY - JOUR AU - Thatte, U. AU - Hussain, S. AU - de Rosas-Valera, M. AU - Malik, M. A. PY - 2009 DA - 2009// TI - Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan JO - Value Health VL - 12 UR - https://doi.org/10.1111/j.1524-4733.2009.00622.x DO - 10.1111/j.1524-4733.2009.00622.x ID - Thatte2009 ER - TY - JOUR AU - Teerawattananon, Y. AU - Tantivess, S. AU - Yothasamut, J. AU - Kingkaew, P. AU - Chaisiri, K. PY - 2009 DA - 2009// TI - Historical development of health technology assessment in Thailand JO - Int J Technol Assess Health Care VL - 25 UR - https://doi.org/10.1017/S0266462309090709 DO - 10.1017/S0266462309090709 ID - Teerawattananon2009 ER - TY - STD TI - PHARMAC: Prescription for Pharmacoeconomic Analysis: Methods for cost-utility analysis. 2012; http://www.pharmac.health.nz/assets/pfpa-final.pdf. Accessed February 23, 2015. UR - http://www.pharmac.health.nz/assets/pfpa-final.pdf ID - ref10 ER - TY - JOUR AU - Towse, A. AU - Garrison, L. P. PY - 2010 DA - 2010// TI - Can’t get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11314080-000000000-00000 DO - 10.2165/11314080-000000000-00000 ID - Towse2010 ER - TY - JOUR AU - Lu, C. Y. PY - 2014 DA - 2014// TI - Uncertainties in real-world decisions on medical technologies JO - Int J Clin Pract VL - 68 UR - https://doi.org/10.1111/ijcp.12434 DO - 10.1111/ijcp.12434 ID - Lu2014 ER - TY - JOUR AU - Carlson, J. J. AU - Sullivan, S. D. AU - Garrison, L. P. AU - Neumann, P. J. AU - Veenstra, D. L. PY - 2010 DA - 2010// TI - Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers JO - Health Policy VL - 96 UR - https://doi.org/10.1016/j.healthpol.2010.02.005 DO - 10.1016/j.healthpol.2010.02.005 ID - Carlson2010 ER - TY - STD TI - Australian Government Department of Human Services: Complex Authority Required Highly Specialised Drugs (CAR HSD). http://www.humanservices.gov.au/health-professionals/services/highly-specialised-drugs/. Accessed February 23, 2015. UR - http://www.humanservices.gov.au/health-professionals/services/highly-specialised-drugs/ ID - ref14 ER - TY - JOUR AU - Stafinski, T. AU - McCabe, C. J. AU - Menon, D. PY - 2010 DA - 2010// TI - Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11530820-000000000-00000 DO - 10.2165/11530820-000000000-00000 ID - Stafinski2010 ER - TY - STD TI - Australian Government Department of Health: Pharmaceutical Benefits Scheme Schedule. http://www.pbs.gov.au/pbs/home. Accessed February 23, 2015. UR - http://www.pbs.gov.au/pbs/home ID - ref16 ER - TY - STD TI - Australian Government Department of Health: Therapeutic Relativity Sheets. http://pbs.gov.au/info/industry/pricing/pbs-items/therapeutic-relativity-sheets. Accessed February 23, 2015. UR - http://pbs.gov.au/info/industry/pricing/pbs-items/therapeutic-relativity-sheets ID - ref17 ER - TY - STD TI - Australian Government Department of Health: Public Summary Documents. http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd. Accessed February 23, 2015. UR - http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd ID - ref18 ER - TY - JOUR AU - Robertson, J. AU - Walkom, E. J. AU - Henry, D. A. PY - 2009 DA - 2009// TI - Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme JO - Aust Health Rev VL - 33 UR - https://doi.org/10.1071/AH090192 DO - 10.1071/AH090192 ID - Robertson2009 ER - TY - JOUR AU - Adamski, J. AU - Godman, B. AU - Ofierska-Sujkowska, G. AU - Osińska, B. AU - Herholz, H. AU - Wendykowska, K. AU - Laius, O. AU - Jan, S. AU - Sermet, C. AU - Zara, C. AU - Kalaba, M. AU - Gustafsson, R. AU - Garuolienè, K. AU - Haycox, A. AU - Garattini, S. AU - Gustafsson, L. L. PY - 2010 DA - 2010// TI - Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers JO - BMC Health Serv Res VL - 10 UR - https://doi.org/10.1186/1472-6963-10-153 DO - 10.1186/1472-6963-10-153 ID - Adamski2010 ER - TY - STD TI - Pugatch M, Healy P, Chu R: Sharing the Burden: Could Risk-Sharing Change the Way We Pay for Healthcare? The Stockholm Network; 2010. http://www.stockholm-network.org/downloads/publications/Sharing_the_Burden.pdf. Accessed February 23, 2015. UR - http://www.stockholm-network.org/downloads/publications/Sharing_the_Burden.pdf ID - ref21 ER - TY - JOUR AU - Lee, E. K. AU - Kim, B. Y. AU - Lim, J. Y. AU - Park, M. H. PY - 2012 DA - 2012// TI - Different policy outcomes of the new drugs and currently listed drugs under the positive list system in South Korea JO - Value Health VL - 15 UR - https://doi.org/10.1016/j.jval.2011.11.017 DO - 10.1016/j.jval.2011.11.017 ID - Lee2012 ER - TY - JOUR AU - Raftery, J. P. PY - 2008 DA - 2008// TI - Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand JO - Med J Aust VL - 188 ID - Raftery2008 ER - TY - JOUR AU - Antonanzas, F. AU - Juarez-Castello, C. AU - Rodriguez-Ibeas, R. PY - 2011 DA - 2011// TI - Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach JO - Health Econ Policy Law VL - 6 UR - https://doi.org/10.1017/S1744133111000016 DO - 10.1017/S1744133111000016 ID - Antonanzas2011 ER - TY - STD TI - Access Economics Pty Limited. The Economic Cost of Arthritis in New Zealand in 2010: Arthritis New Zealand; 2010. http://www.arthritis.org.nz/wp-content/uploads/2011/07/economic-cost-of-arthritis-in-new-zealand-final-print.pdf. Accessed February 23, 2015. UR - http://www.arthritis.org.nz/wp-content/uploads/2011/07/economic-cost-of-arthritis-in-new-zealand-final-print.pdf ID - ref25 ER - TY - STD TI - PHARMAC: Decision Criteria. http://www.pharmac.health.nz/medicines/how-medicines-are-funded/decision-criteria/. Accessed February 23, 2015. UR - http://www.pharmac.health.nz/medicines/how-medicines-are-funded/decision-criteria/ ID - ref26 ER - TY - JOUR AU - Yang, B. M. AU - Bae, E. Y. AU - Kim, J. PY - 2008 DA - 2008// TI - Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance JO - Health Aff VL - 27 UR - https://doi.org/10.1377/hlthaff.27.1.179 DO - 10.1377/hlthaff.27.1.179 ID - Yang2008 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. M. AU - Day, R. O. PY - 2006 DA - 2006// TI - Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? JO - Intern Med J VL - 36 UR - https://doi.org/10.1111/j.1445-5994.2005.00992.x DO - 10.1111/j.1445-5994.2005.00992.x ID - Lu2006 ER - TY - JOUR AU - Owen, A. AU - Spinks, J. AU - Meehan, A. AU - Robb, T. AU - Hardy, M. AU - Kwasha, D. AU - Wlodarczyk, J. AU - Reid, C. PY - 2008 DA - 2008// TI - A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry JO - J Med Econ VL - 11 ID - Owen2008 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. M. AU - Day, R. O. PY - 2006 DA - 2006// TI - Accessing health outcome data on high-cost medicines in Australia JO - Med J Aust VL - 184 ID - Lu2006 ER - TY - JOUR AU - Lu, C. Y. AU - Ritchie, J. AU - Williams, K. AU - Day, R. PY - 2007 DA - 2007// TI - The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia JO - Austr N Z Health Policy VL - 4 UR - https://doi.org/10.1186/1743-8462-4-26 DO - 10.1186/1743-8462-4-26 ID - Lu2007 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. M. AU - Day, R. O. PY - 2007 DA - 2007// TI - The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines JO - Austr N Z Health Policy VL - 4 UR - https://doi.org/10.1186/1743-8462-4-2 DO - 10.1186/1743-8462-4-2 ID - Lu2007 ER - TY - JOUR AU - Lu, C. Y. AU - Macneill, P. AU - Williams, K. AU - Day, R. PY - 2008 DA - 2008// TI - Access to high cost medicines in Australia: ethical perspectives JO - Austr N Z Health Policy VL - 5 UR - https://doi.org/10.1186/1743-8462-5-4 DO - 10.1186/1743-8462-5-4 ID - Lu2008 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. M. AU - March, L. AU - Bertouch, J. V. AU - Day, R. O. PY - 2004 DA - 2004// TI - Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible? JO - Med J Aust VL - 181 ID - Lu2004 ER - TY - JOUR AU - McCabe, C. J. AU - Stafinski, T. AU - Edlin, R. AU - Menon, D. AU - Banff, A. E. D. S. PY - 2010 DA - 2010// TI - Access with evidence development schemes: a framework for description and evaluation JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11530850-000000000-00000 DO - 10.2165/11530850-000000000-00000 ID - McCabe2010 ER - TY - JOUR AU - Lassarat, S. AU - Jootar, S. PY - 2006 DA - 2006// TI - Ongoing challenges of a global international patient assistance program JO - Ann Oncol VL - 17 ID - Lassarat2006 ER - TY - BOOK PY - 2008 DA - 2008// TI - Notification of the Ministry of Public Health: Re: Exercising of right on pharmaceuticals products patent for imatinib, dated 25th January, B.E. 2551 PB - Ministry of Public Health CY - Nonthaburi ID - ref37 ER - TY - STD TI - IMS Institute for Healthcare Informatics: The Global Use of Medicines: Outlook through 2017. 2013; http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf. Accessed February 23, 2015. UR - http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf ID - ref38 ER - TY - JOUR AU - Lu, C. Y. AU - Williams, K. AU - Day, R. PY - 2008 DA - 2008// TI - Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia JO - Int J Rheum Dis VL - 11 UR - https://doi.org/10.1111/j.1756-185X.2008.00322.x DO - 10.1111/j.1756-185X.2008.00322.x ID - Lu2008 ER -